Clinical trials: Allogeneic Disease
Acute Lymphocytic Leukemia
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
The safety and efficacy of the chimeric antigen receptor (CAR)-T, a CD19-targeting, TRAC and Power3 (SPPL3) double gene deleted allogeneic CAR-T cell product, are undergoing rigorous evaluation in non-Hodgkin's lymphoma (NHL)…
- Trial name
- NCT06481735
- Testing
- TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell, Fludarabine, Cyclophosphamide
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Hematopoietic Stem Cell Transplantation, Hematologic Malignancy
αβT Cell/CD19+ B Cell Depletion for Alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)
This is a study utilizing the Magnetic-activated cell sorting (CliniMACS®) Alpha-Beta T-cell (αβT)/Cluster of Differentiation 19 (CD19), also called B lymphocyte antigen CD19 depletion device for Children and Young Adults with…
- Trial name
- TB19DHCT (NCT06082947)
- Testing
- CliniMACS®
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Nationwide Children's Hospital
Allogeneic Disease
APOLLO: Personalized rehAbilitation PrOgram in aLLOgeneic Bone Marrow Transplantation
People who undergo allogeneic bone marrow transplant for blood cancers receive the highest chemotherapy doses possible that humans can receive and still survive.
- Trial name
- APOLLO (NCT05579678)
- Testing
- Supportive nursing, nutritional and physical activity with a handheld 'app'
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- University of Alberta
Myelodysplastic Syndrome, Leukemia
Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)
Primary Objective: -To determine the dose and schedule combination of 5-Azacitidine, when used as maintenance treatment after allogeneic transplantation for high-risk AML / MDS.
- Trial name
- NCT00350818
- Testing
- Azacitidine
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphocytic Leukemia, Lymphoma
In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
The purpose of this study is to test the safety of giving the patient special cells from a donor called "Modified T-cells". The goal is to assess the toxicities of T-cells for patients with relapsed B cell leukemia or lymphoma…
- Trial name
- NCT01430390
- Testing
- Biological/Genetically Modified T cells, Cyclophosphamide-based chemotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myeloid Leukemia
Reduced Intensity AlloSCT in(CML) With Persistent Disease
CML, a malignant disorder of stem cells, is characterized by increases in both immature and mature myeloid, erythroid, and lymphoid cells, as well as platelets in the peripheral blood.
- Trial name
- CML (NCT00531310)
- Testing
- Reduced Intensity Conditioning, Busulfan and Fludarabine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Columbia University
Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation
Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML
The purpose of this study is to reveal the influence of co-existing mutations on the efficacy of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for patients with FLT3-ITD AML.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT04788420
- Testing
- Sorafenib
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Myelodysplastic Syndromes
A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score
Figure out the Efficacy and Safety of Azacitidine Combined with BUCY2 Conditioning Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome with Moderate High IPSS-M Score
- Trial name
- NCT06279338
- Testing
- Azacitidine Injection
- Volunteers
- 40 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gingival Recession
Treatment of Gingival Recession Defects Using Platelet-Rich Fibrin With an Allogenic Dermal Matrix
The study aims to test the non-inferiority of an Allogenic Dermal Matrix with Platelet-Rich Fibrin for treatment of gingival recessions in comparison to the Connective Tissue Graft.
- Trial name
- NCT05819515
- Testing
- Tunneled coronally advanced flap
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Peripheral Vascular Diseases
Phase I/II Trial of Endometrial Regenerative Cells (ERC) in Patients With Critical Limb Ischemia
This is a 15 patient clinical trial assessing the safety and feasibility of using Endometrial Regenerative Cells (ERC) in patients with critical limb ischemia (CLI) that are not eligible for surgical or catheter-based…
- Trial name
- NCT01558908
- Testing
- Administration of ERC
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Medistem Inc.
Acute Myeloid Leukemia
CNDO-109-AANK for AML in First Complete Remission (CR1)
This is a multi-center, open-label, non-controlled, non-randomized dose-escalating Phase 1 clinical study designed to examine the safety of infusing escalating doses of CNDO-109-Activated Allogeneic Natural Killer Cells-(from a…
- Trial name
- NCT01520558
- Testing
- CNDO-109-AANK Cells
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Coronado Biosciences, Inc.
Hematologic Malignancy, Leukemia
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
This phase II clinical trial studies how well two donors stem cell transplant work in treating patients with high-risk hematologic malignancies.
- Conditions
- Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia, ALL
- Trial name
- NCT01532635
- Testing
- Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
This phase II trial studies how well vorinostat and combination chemotherapy before donor stem cell transplantation work in treating patients with aggressive B-cell or T-cell non-Hodgkin lymphoma that has come back (relapsed).
- Conditions
- Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04220008
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Clofarabine
- Sponsor
- M.D. Anderson Cancer Center
Lateral Epicondylitis
Treatment of Tendon Injury Using Mesenchymal Stem Cells
Main purpose of this study is to evaluate efficacy and safety of allogenic adipose-derived mesenchymal stem cells(ALLO-ASC) in treatment of tendon injury.
- Trial name
- ALLO-ASC (NCT01856140)
- Testing
- ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Seoul National University Hospital
Peripheral Neuropathy, Trigeminal Neuralgia
Safety of Cultured Allogeneic Adult Umbilical Cordor Placental Derived Stem Cells Exosomes for Trigeminal Neuralgia
This trial will study the safety and efficacy of instillation of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes for the treatment of Trigeminal Neuralgia.
- Trial name
- NCT05152368
- Testing
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes
- Where
- 2 sites in United States, Greece
- Volunteers
- 20 people
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML
JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or…
- Trial name
- NCT04429191
- Testing
- Humanized anti-CD117 Monoclonal Antibody (JSP191)
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Jasper Therapeutics, Inc.
Graft vs Host Disease
Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation
Atorvastatin for prevention of acute GVHD
- Trial name
- NCT01175148
- Testing
- Atorvastatin calcium (Lipitor)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- West Virginia University
Allogeneic Hematopoietic Stem Cell Transplantation, CMV Infection
CMV-TCR-T Cells for Refractory CMV Infection After HSCT
This is a single centre, single arm, open-label, phase I study to evaluate the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating refractory CMV infection after HSCT.
- Trial name
- NCT05089838
- Testing
- CMV-TCR-T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Xiao-Jun Huang
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
This study will provide long-term follow-up for patients who have received treatment with WU-CART-007 in a previous clinical trial.
- Trial name
- NCT05509855
- Testing
- Genetic: WU-CART-007
- Where
- 5 sites in United States, Australia
- Volunteers
- 44 people
- Sponsor
- Allotera Therapeutics
Adenovirus
Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia
This is a randomized, controlled, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetic (PK), and adenovirus (AdV) antiviral activity of multiple ascending doses of IV brincidofovir (BCV).
- Trial name
- NCT03532035
- Testing
- Brincidofovir, Standard of Care
- Where
- 8 sites in United States, Italy and 1 more
- Sponsor
- Jazz Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.